The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


DICP, The Annals of Pharmacotherapy: Vol. 25, No. 5, pp. 525-531.
© 1991 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garrelts, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garrelts, J.


Research Articles

Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection

JC Garrelts

This article reviews the chemistry, pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy in leprosy and Mycobacterium avium complex (MAC) infection, adverse effects, drug interactions, and special considerations of clofazimine. The drug is active in vivo against M. leprae and in vitro against MAC. In addition, it possesses antiinflammatory and immunosuppressive properties. Clinical studies support the efficacy of clofazimine as a part of multidrug therapy in treating leprosy. It also appears to reduce the incidence and severity of erythema nodosum leprosum reactions that often occur during the treatment of leprosy. Efficacy in treating MAC infection in patients with AIDS is not well documented, despite the use of clofazimine in combination with other agents. A few patients have responded symptomatically and by clearing their mycobacteremia, although there is no evidence that mortality is reduced. Clofazimine is well tolerated, at least when doses less than or equal to 100 mg/d are used. Adverse reactions include discoloration of the skin, self-limiting gastrointestinal intolerance, severe and life-threatening abdominal pain and organ damage due to clofazimine crystal deposition, and asymptomatic discoloration of the eye. Clofazimine should be considered for formulary inclusion.


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
L. B. Adams, I. Sinha, S. G. Franzblau, J. L. Krahenbuhl, and R. T. Mehta
Effective Treatment of Acute and Chronic Murine Tuberculosis with Liposome-Encapsulated Clofazimine
Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1638 - 1643.
[Abstract] [Full Text]


Home page
J Antimicrob ChemotherHome page
V. M. Reddy, J. F. O' Sullivan, and P. R. J. Gangadharam
Antimycobacterial activities of riminophenazines
J. Antimicrob. Chemother., May 1, 1999; 43(5): 615 - 623.
[Abstract] [Full Text] [PDF]


Home page
The Journal of School NursingHome page
B. Gravatt
Current Concepts in the Pharmacologic Treatment and Management of Tuberculosis
The Journal of School Nursing, October 1, 1997; 13(4): 28 - 38.
[Abstract] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1991 by Harvey Whitney Books Company.